Please use this identifier to cite or link to this item:
https://doi.org/10.1016/S0140-6736(21)01378-7
| Title: | What are the obligations of pharmaceutical companies in a global health emergency? | Authors: | Emanuel, EJ Buchanan, A Chan, SY Fabre, C Halliday, D Heath, J Herzog, L Leland, RJ McCoy, MS Norheim, OF Saenz, C Schaefer, GO Tan, KC Wellman, CH Wolff, J Persad, G |
Keywords: | Costs and Cost Analysis Developing Countries Drug Industry Global Health Humans Social Responsibility |
Issue Date: | 11-Sep-2021 | Publisher: | Elsevier BV | Citation: | Emanuel, EJ, Buchanan, A, Chan, SY, Fabre, C, Halliday, D, Heath, J, Herzog, L, Leland, RJ, McCoy, MS, Norheim, OF, Saenz, C, Schaefer, GO, Tan, KC, Wellman, CH, Wolff, J, Persad, G (2021-09-11). What are the obligations of pharmaceutical companies in a global health emergency?. The Lancet 398 (10304) : 1015-1020. ScholarBank@NUS Repository. https://doi.org/10.1016/S0140-6736(21)01378-7 | Source Title: | The Lancet | URI: | https://scholarbank.nus.edu.sg/handle/10635/228267 | ISSN: | 01406736 1474547X |
DOI: | 10.1016/S0140-6736(21)01378-7 |
| Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
| File | Description | Size | Format | Access Settings | Version | |
|---|---|---|---|---|---|---|
| What are the obligations of pharmaceutical companies in a global health emergency.pdf | 154.86 kB | Adobe PDF | CLOSED | None |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.